The success rate of targeted therapies varies depending on the specific mutation and cancer type. In some cases, targeted therapies have significantly improved survival rates and quality of life. For instance, EGFR inhibitors like erlotinib and gefitinib have shown remarkable efficacy in patients with EGFR-mutant NSCLC. However, the development of resistance over time is a major challenge, necessitating continuous research for new targets and combination therapies.
